Celltex’s Stem Cell Manufacturing To Be Regulated As A Biological Drug
This article was originally published in The Pink Sheet Daily
FDA tells Celltex Therapeutics that its stem cell treatments are to be regulated as biologics; company contends they should be considered a human cell and tissue product.
You may also be interested in...
FDA finds the company failed to establish procedures for a range of GMP basics, which is a problem because according to the agency the IntelliCell adipose tissue-derived stem cells are both a drug and a biologic product.
FDA’s 2019 survey of 2,000 providers finds 31% do not know what biosimilars are and 30% of primary care physicians do not know what an accelerated approval drug is. Another survey of low- or non-internet users finds a toll-free number is the best way for them to find information about a drug’s risks.
Industry executives note lessons learned from ‘fascinating’ approaches DOJ and states have taken in recent settlements, from restrictions on Novartis speaker programs to targeting McKinsey’s marketing advice. Chart includes details of 18 settlements since January 2020.